Even while CCR6 is not considered a typical checkpoint inhibitor, some evidence suggests that targeting CCR6 may enhance the efficacy of immune checkpoint inhibitors in treating certain types of cancer, including CRC [85]. The gene discussed is CCR6; the disease is colorectal carcinoma.